USPTO Examiner WOOLWINE SAMUEL C - Art Unit 1681

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19228005ANALYSIS OF A POLYNUCLEOTIDE VIA A NANOPORE SYSTEMJune 2025October 2025Allow410YesNo
18986602ESTIMATING TUMOR PURITY FROM SINGLE SAMPLESDecember 2024August 2025Allow811NoNo
18885331DETECTION OF METHYLATION STATUS OF A DNA SAMPLESeptember 2024May 2025Allow811YesNo
18673376METHOD FOR SCREENING LACTOBACILLUS CASEI FERMENTATION AGENTMay 2024October 2024Allow510NoNo
18576506METHOD FOR COLD PLASMA INDUCED CELL DEATH IN BREAST CANCER CELLS BY 8-OXOG MODIFICATION AND DEGRADATION OF HISTONE MRNAJanuary 2024May 2025Allow1620NoNo
18330279METHODS FOR ASSEMBLING AND READING NUCLEIC ACID SEQUENCES FROM MIXED POPULATIONSJune 2023October 2024Abandon1620NoNo
18122246Methods for Characterization of Viral Genome Using Base ModificationsMarch 2023February 2026Allow3510NoNo
18115405METHODS FOR SEPARATING AND DETECTING DOUBLE-STRANDED AND SINGLE-STRANDED RIBONUCLEIC ACID (RNA)February 2023February 2026Allow3610NoNo
18173060SPECIFIC DNA FRAGMENT OF FEMALE ACIPENSER DABRYANUS AND METHOD FOR IDENTIFYING THE SEX OF ACIPENSER DABRYANUSFebruary 2023May 2024Allow2720NoNo
18064892Multiplex Q-PCR ArraysDecember 2022September 2025Abandon3310NoNo
18076214RNA SEQUENCING METHODSDecember 2022September 2025Allow3300NoNo
18073515METHOD AND APPARATUS FOR THE ANALYSIS AND IDENTIFICATION OF MOLECULESDecember 2022March 2026Abandon4010NoNo
17992668METHODS OF DETECING LUNG CANCERNovember 2022September 2025Allow3410NoNo
18052811L-RNA APTAMERS AND METHODS OF IDENTIFYING THE SAMENovember 2022January 2026Allow3810NoNo
18045369FAST AND ROBUST BI-FUNCTIONAL MUTANTS OF TAQ DNA POLYMERASEOctober 2022February 2026Allow4010NoNo
17916140METHOD OF DETECTING AN ANALYTE IN A MEDIUM COMPRISING A LIGHT SCATTERING CONSTITUENTSeptember 2022February 2026Allow4010NoNo
17915832PRIMER SET AND PROBE FOR DETECTING STAPHYLOCOCCUS ARGENTEUSSeptember 2022December 2025Abandon3910NoNo
17933442Multiplex Q-PCR ArraysSeptember 2022August 2025Abandon3510NoNo
17932895SPATIAL-DEPENDENT ANALYSIS OF BIOLOGICAL MATERIAL FROM INTACT TISSUE SAMPLESSeptember 2022February 2026Allow4110NoNo
17293412ELECTRONIC DETECTION OF NUCLEIC ACID STRUCTURESeptember 2022July 2025Allow5010NoNo
17905659Viral multimeric peptide constructs for targeting PDZ domainsSeptember 2022February 2026Abandon4110NoNo
17758828HIGH THROUGHPUT GENETIC BARCODING AND ANALYSIS METHODSJuly 2022December 2025Allow4110NoNo
17864913LABELING STRATEGY FOR USE IN DNA SEQUENCING TO FACILITATE ASSEMBLY OF SEQUENCE READS INTO LONGER FRAGMENTS OF A GENOMEJuly 2022May 2025Allow3410NoNo
17863110METHODS AND DEVICES FOR MEASURING DUPLEX UNWINDING OR STRAND EXCHANGE EFFICIENCYJuly 2022March 2026Allow4420NoNo
17855325FLOW CELLSJune 2022September 2025Allow3910NoNo
17852737GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISEASES, METHODS OF DETECTION AND USES THEREOFJune 2022September 2025Abandon3901NoNo
17847210SEX IDENTIFICATION SPECIFIC DNA SEQUENCE AND SEX IDENTIFICATION METHOD OF CHINESE MITTEN CRAB ERIOCHEIR SINENSISJune 2022September 2025Allow3920NoNo
17757861SIMPLIFIED POLYNUCLEOTIDE SEQUENCE DETECTION METHODJune 2022December 2025Allow4220NoNo
17835439DIGITAL ANALYTE ANALYSISJune 2022August 2025Allow3810NoNo
17829158METHODS FOR LABELLING NUCLEIC ACIDSMay 2022September 2025Allow4011NoNo
17824215METHODS AND PROBES FOR PERFORMING PCR WITH MELT ANALYSIS FOR INCREASED MULTIPLEXINGMay 2022January 2025Allow3200NoNo
17735904Estimating Tumor Purity From Single SamplesMay 2022September 2024Allow2910YesNo
17731006Nucleic Acid TaggantsApril 2022February 2025Allow3320YesNo
17728463METHODS FOR STANDARDIZED SEQUENCING OF NUCLEIC ACIDS AND USES THEREOFApril 2022July 2025Allow3810NoNo
17725127DEVICES AND METHODS FOR LOADING OF FLUIDIC RECEPTACLESApril 2022November 2025Abandon4301NoNo
17763998METHOD OF PREDICTING PRODUCTION STABILITY OF CLONAL CELL LINESMarch 2022October 2025Abandon4310NoNo
17700373COMPOSITIONS AND METHODS FOR MOLECULAR LABELINGMarch 2022September 2024Allow3060NoNo
17698897PRECISION MEDICINE PORTAL FOR HUMAN DISEASESMarch 2022October 2025Abandon4301NoNo
17761419KIT AND METHOD OF USING KITMarch 2022January 2026Abandon4611NoNo
17641518INSTRUMENT AND METHOD FOR EXTRACTING AND DETECTING NUCLEIC ACIDSMarch 2022January 2026Allow4710NoNo
17286421PHASE-ISOLATED WATER-IN-OIL TRANSPARENT MACROEMULSION AND APPLICATION THEREOFMarch 2022September 2025Abandon5310NoNo
17679310COMPOSITIONS AND METHODS FOR MOLECULAR LABELINGFebruary 2022September 2025Allow4380YesNo
17636591METHOD FOR AMPLIFYING NUCLEOTIDE SEQUENCE AND SEQUENCE DETERMINATIONFebruary 2022November 2025Allow4520YesNo
17651225NANOPORE-BASED POLYMER ANALYSIS WITH MUTUALLY-QUENCHING FLUORESCENT LABELSFebruary 2022November 2024Abandon3310NoNo
17630004POLYNUCLEOTIDES FOR THE AMPLIFICATION AND DETECTION OF NEISSERIA GONORRHOEAEJanuary 2022April 2025Abandon3810NoNo
17575914DETECTING NUCLEIC ACIDJanuary 2022December 2024Abandon3510NoNo
17568077METHODS AND COMPOSITIONS FOR STABILIZING NUCLEIC ACID-NUCLEOTIDE-POLYMERASE COMPLEXESJanuary 2022May 2025Allow4010NoNo
17562346Small RNA Capture, Detection and QuantificationDecember 2021May 2025Abandon4110NoNo
17547920DEVICES, SYSTEMS AND METHODS FOR BIOMARKER ANALYSISDecember 2021December 2023Abandon2440YesNo
17531270SYSTEMS AND PROCESSES FOR DISTINGUISHING PATHOGENIC AND NON-PATHOGENIC SEQUENCES FROM SPECIMENSNovember 2021April 2025Allow4110NoNo
17529082COMPOSITIONS AND METHODS FOR MOLECULAR LABELINGNovember 2021June 2024Allow3150NoNo
17599423Shape-Responsive NanostructuresSeptember 2021January 2025Allow4010NoNo
17470828PCR TUBE, APPARATUS FOR PCR INCLUDING THE SAME AND PCR METHOD USING THE SAMESeptember 2021November 2024Allow3810NoNo
17458995NUCLEIC ACID ANALYSIS BY JOINING BARCODED POLYNUCLEOTIDE PROBESAugust 2021January 2025Allow4110NoNo
17434293AN IMPROVED METHOD OF PREPARING CLINICAL SAMPLES FOR NUCLEIC ACID AMPLIFICATIONAugust 2021May 2025Allow4410NoNo
17397280UNIVERSAL SANGER SEQUENCING FROM NEXT-GEN SEQUENCING AMPLICONSAugust 2021November 2024Allow3920NoNo
17397320METHOD OF CHARACTERIZING A TARGET RIBONUCLEIC ACID (RNA) COMPRISING FORMING A COMPLEMENTARY POLYNUCLEOTIDE WHICH MOVES THROUGH A TRANSMEMBRANE POREAugust 2021July 2025Allow4720NoNo
17427266MULTIPLEX PCR METHOD USING APTAMERJuly 2021March 2025Abandon4310NoNo
17369796SEQUENCES FOR DETECTION AND IDENTIFICATION OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) OF MREJ TYPE XXIJuly 2021March 2025Abandon4420NoNo
17369834ANALYSIS OF A POLYNUCLEOTIDE VIA A NANOPORE SYSTEMJuly 2021March 2025Allow4410NoNo
17356402METHOD FOR DETECTING CHIKUNGUNYA VIRUSJune 2021February 2025Allow4430YesNo
17346077NUCLEIC ACID ASSAYS USING CLICK CHEMISTRY BIOCONJUGATIONJune 2021September 2024Allow6010NoNo
17336055OLIGONUCLEOTIDES AND BEADS FOR 5 PRIME GENE EXPRESSION ASSAYJune 2021July 2024Allow3811NoNo
17316416METHOD FOR LABEL-FREE SINGLE-MOLECULE DNA SEQUENCING AND DEVICE FOR IMPLEMENTING SAMEMay 2021December 2024Abandon4310NoNo
17289499Compositions and Methods for Discriminating Infectious from Non-Infectious CNS DisordersApril 2021November 2024Abandon4201NoNo
17236889TERMINAL FUNCTIONALIZATION OF TARGET MOLECULES FOR SEQUENCINGApril 2021December 2024Abandon4420NoNo
17283968CATALYTIC BIOMOLECULE ACTIVITY RECORDING INTO DNA SEQUENCEApril 2021September 2024Allow4210NoNo
16760185INTRAORAL EXAMINATION METHOD USING INFORMATION ON BACTERIAL GROUP RELATED TO CLINICAL INDEXESApril 2021March 2026Abandon6040YesNo
17264427METHOD FOR THE QUALITY CONTROL OF SEED LOTSJanuary 2021March 2026Abandon6040NoNo
17126693METHOD OF NONSPECIFIC TARGET CAPTURE OF NUCLEIC ACIDSDecember 2020September 2024Allow4541NoNo
17120518DETECTING CHOLANGIOCARCINOMADecember 2020August 2024Allow4440YesNo
16953547DETERMINATION OF CELLS USING AMPLIFICATIONNovember 2020October 2025Abandon5960NoNo
17070190Methods for Making Nucleotide Probes for Sequencing and SynthesisOctober 2020August 2024Allow4621NoNo
17046552DNA-TAGGED METHANOL RESPONSIVE POLYMER FOR SINGLE-STRANDED NUCLEIC ACID PRODUCTIONOctober 2020December 2023Allow3830NoNo
17036401DETERMINISTIC BARCODING FOR SPATIAL OMICS SEQUENCINGSeptember 2020July 2024Allow4631NoNo
16979481METHODS OF SEQUENCING NUCLEIC ACIDS AND ERROR CORRECTION OF SEQUENCE READSSeptember 2020August 2024Allow4740NoNo
16970318METHODS AND COMPOSITIONS FOR RICKETTSIACEAE DETECTIONAugust 2020April 2025Abandon5631NoNo
16964386HYBRIDIZATION CHAIN REACTION-BASED METHOD FOR AMPLIFYING IMMUNOSIGNALSJuly 2020November 2024Allow5230NoNo
16869481METHODS AND COMPOSITIONS FOR NUCLEIC ACID DETECTIONMay 2020May 2025Abandon6041NoNo
16628828HIGH-COVERAGE AND ULTRA-ACCURATE IMMUNE REPERTOIRE SEQUENCING USING MOLECULAR IDENTIFIERSJanuary 2020February 2025Abandon6041YesNo
16611190METHOD AND APPARATUS FOR CAPTURING HIGH-PURITY NUCLEOTIDESNovember 2019July 2025Allow6060YesNo
16608014DIRECT NUCLEIC ACID ANALYSIS OF ENVIRONMENTAL AND BIOLOGICAL SAMPLESOctober 2019August 2025Abandon6070NoNo
16596587SIMULTANEOUS QUANTIFICATION OF A PLURALITY OF PROTEINS IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUEOctober 2019June 2025Allow6051YesNo
16544727METHODS FOR QUANTIFYING EFFICIENCY OF NUCLEIC ACID EXTRACTION AND DETECTIONAugust 2019September 2025Allow6081YesNo
16444619METHODS FOR NON-INVASIVE PRENATAL PLOIDY CALLINGJune 2019August 2024Allow6041YesNo
16347387METHOD FOR DETERMINING A HEAD AND NECK SQUAMOUS CELL CARCINOMAMay 2019March 2025Allow6051YesNo
15785680Low Sequence Bias Single-Stranded DNA LigationOctober 2017December 2019Allow2610NoNo
15587944DETECTING NUCLEIC ACIDMay 2017December 2019Allow3110NoNo
15442864DNA SEQUENCING AND PROCESSINGFebruary 2017August 2019Allow3000YesNo
15285421Compositions And Methods For Immunodominant AntigensOctober 2016August 2018Allow2300NoNo
15271269REAL-TIME PCR POINT MUTATION ASSAYS FOR DETECTING HIV - 1 RESISTANCE TO ANTIVIRAL DRUGSSeptember 2016September 2019Allow3521YesNo
15056475COMBINED THERMAL DEVICES FOR THERMAL CYCLINGFebruary 2016November 2018Allow3310NoNo
14931716EXOSOMES AND MICROVESICLES IN INTESTINAL LUMINAL FLUIDS AND STOOL AND USE OF SAME FOR THE ASSESSMENT OF INFLAMMATORY BOWEL DISEASENovember 2015December 2018Allow3711NoNo
14765782METHOD FOR MEASURING BONE LOSS RATEAugust 2015February 2018Allow3020NoNo
14702628METHODS AND GENOTYPING PANELS FOR DETECTING ALLELES, GENOMES, AND TRANSCRIPTOMESMay 2015January 2018Allow3200NoNo
14395239METHODS FOR REAL-TIME SAMPLING OF REACTION PRODUCTSOctober 2014October 2017Allow3611NoNo
14512694Digital AmplificationOctober 2014January 2018Allow3911NoNo
14472155SPERM CELL SEPARATION METHODS AND COMPOSITIONS CONTAINING APTAMERS OR NUCLEIC ACID SEQUENCES FOR USE THEREINAugust 2014June 2016Allow2210NoNo
14036527DOUBLE STRANDED LINEAR NUCLEIC ACID PROBESeptember 2013March 2016Allow3010YesNo
13748380DETECTION, IDENTIFICATION AND DIFFERENTIATION OF EUBACTERIAL TAXA USING A HYBRIDIZATION ASSAYJanuary 2013October 2015Allow3320NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WOOLWINE, SAMUEL C.

Strategic Value of Filing an Appeal

Total Appeal Filings
16
Allowed After Appeal Filing
6
(37.5%)
Not Allowed After Appeal Filing
10
(62.5%)
Filing Benefit Percentile
61.3%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 37.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner WOOLWINE, SAMUEL C - Prosecution Strategy Guide

Executive Summary

Examiner WOOLWINE, SAMUEL C works in Art Unit 1681 and has examined 171 patent applications in our dataset. With an allowance rate of 88.9%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 43 months.

Allowance Patterns

Examiner WOOLWINE, SAMUEL C's allowance rate of 88.9% places them in the 70% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.

Office Action Patterns

On average, applications examined by WOOLWINE, SAMUEL C receive 2.56 office actions before reaching final disposition. This places the examiner in the 75% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by WOOLWINE, SAMUEL C is 43 months. This places the examiner in the 16% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +4.5% benefit to allowance rate for applications examined by WOOLWINE, SAMUEL C. This interview benefit is in the 29% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 25.6% of applications are subsequently allowed. This success rate is in the 41% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 45.8% of cases where such amendments are filed. This entry rate is in the 70% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 87% percentile among all examiners. Of these withdrawals, 93.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 83.3% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 22.2% of allowed cases (in the 98% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 15.8% of allowed cases (in the 92% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.